drugset / Trial / NCT07285291

A Phase 3 Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis With Phosphate Binders

NCT07285291

Phase 3 Recruiting 100 enrolled Taisho Pharmaceutical Co., Ltd.
RandomizedParallel-groupTriple-blindTreatment

Summary

A phase 3, randomized, placebo-controlled, double-blind, phosphate binder-combination study of TS-172 in hyperphosphatemia patients on hemodialysis

Timeline

Start
2026-01-09
Primary completion
2026-12-22
Completion
2026-12-29

Drugs

EvaluationDrugModalityDoseRoute
Subject TS-172 Unknown 20 mg Oral
Subject TS-172 Unknown 60 mg Oral

Indications